BeiGene Ltd ADR [BGNE] stock prices are up 7.77% to $176.47 at the moment. An important factor to consider is whether the stock is rising or falling in short-term value. The BGNE shares have gain 10.63% over the last week, with a monthly amount glided 20.40%, and seem to be holding up well over a long-time horizon.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
On 13, March 2024, First Doses of BRUKINSA® provided to Patients with Chronic Lymphocytic Leukemia in Low- and Middle-Income Countries Under Collaboration of The Max Foundation, BeiGene, and the BeiGene Foundation. In a post published today on Yahoo Finance, Armenia and Nepal are the first of 29 countries to receive BRUKINSA.
From an analyst’s perspective:
Previously, Macquarie started tracking the stock with Outperform rating on September 12, 2023, and set its price target to $259. On August 17, 2023, Jefferies initiated with a Buy rating and assigned a price target of $287 on the stock. Citigroup started tracking the stock assigning a Buy rating and suggested a price target of $275 on July 17, 2023. Bernstein downgraded its rating to a Mkt Perform and reduced its price target to $196 on June 30, 2023. Daiwa Securities started tracking with a Buy rating for this stock on January 12, 2023, and assigned it a price target of $308. In a note dated October 13, 2022, SVB Leerink upgraded an Outperform rating on this stock and boosted its target price from $177 to $200.
The stock price of BeiGene Ltd ADR [BGNE] has been fluctuating between $132.95 and $272.49 over the past year. Currently, Wall Street analysts expect the stock to reach $200.5 within the next 12 months. BeiGene Ltd ADR [NASDAQ: BGNE] shares were valued at $176.47 at the most recent close of the market. An investor can expect a potential return of 13.62% based on the average BGNE price forecast.
Analyzing the BGNE fundamentals
The BeiGene Ltd ADR [NASDAQ:BGNE] reported sales of 2.46B for trailing twelve months, representing a surge of 66.91%. Gross Profit Margin for this corporation currently stands at 0.66% with Operating Profit Margin at -0.49%, Pretax Profit Margin comes in at -0.34%, and Net Profit Margin reading is -0.36%. To continue investigating profitability, this company’s Return on Assets is posted at -0.15, Equity is -0.23 and Total Capital is -0.3. An extended analysis of the company’s primary financial structure reveals a debt-to-equity ratio of0.26.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 173.04 points at the first support level, and at 169.61 for the second support level. However, for the 1st resistance point, the stock is sitting at 182.35, and for the 2nd resistance point, it is at 188.23.
BeiGene Ltd ADR [BGNE] reported earnings per share of -$3.53 for its fiscal quarter that ended on 12/30/2023. Based on the Wall Street analysts’ estimates, the company was expected to report earnings of -$3.96/share, meaning a difference of $0.43 and a surprise factor of 10.90%. By comparison, the stated earnings for the previous quarter ended on 9/29/2023 were $2.01 per share as compared to estimates of -$3.11 per share, a difference of $5.12 representing a surprise of 164.60%.
Ratios To Look Out For
It’s worth pointing out that BeiGene Ltd ADR [NASDAQ:BGNE]’s Current Ratio is 2.32. On the other hand, the Quick Ratio is 2.09, and the Cash Ratio is 1.76. Considering the valuation of this stock, the price to sales ratio is 6.85, the price to book ratio is 5.22.
Transactions by insiders
Recent insider trading involved Wang Julia Aijun, Chief Financial Officer, that happened on Feb 29 ’24 when 397.0 shares were sold. SVP, General Counsel, Lee Chan Henry completed a deal on Jul 31 ’23 to sell 791.0 shares. Meanwhile, Chief Financial Officer Wang Julia Aijun sold 472.0 shares on Jul 03 ’23.
